Lexicon CEO Mike Exton expressed confidence in pilavapadin's potential, positioning it as the first oral non-opioid treatment for neuropathic pain in …
Source: pain relief
“Each year at Scripps, we evaluate a large, growing number of patients suffering from chronic low back pain,” said Robert Eastlack, MD, Orthopedic …
Source: back pain
Lexicon's non-opioid drug pilavapadin fails Phase 2b pain trial at 20mg dose, but shows promise at 10mg. Company plans Phase 3 advancement and …
Source: pain medication
